AKBA Akebia Therapeutics, Inc.

9.13
+0  (0%)
Previous Close 9.12
Open 9.14
Price To book 5.16
Market Cap 167.08M
Shares 18,300,000
Volume 142,171
Short Ratio 5.66
Av. Daily Volume 225,785

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)

Latest News

  1. Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  2. Akebia to Present at the 16th Annual Needham Healthcare Conference
  3. Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
  4. Why Akebia Therapeutics Inc. Tanked Today
  5. Edited Transcript of AKBA earnings conference call or presentation 6-Mar-17 9:30pm GMT
  6. Akebia Therapeutics reports 4Q loss
  7. Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results
  8. Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights
  9. 3 Biotech Stocks You May Be Overlooking
  10. KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%
  11. The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
  12. Forget Gilead, Buy These 5 Biotech Stocks Instead
  13. Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
  14. Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation
  15. Merrimack Pharmaceuticals employee arrested, charged with insider trading
  16. Concordia International (CXRX) Looks Good: Stock Jumps 11.4%
  17. Akebia to Present at the 19th BIO CEO & Investor Conference
  18. Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
  19. Moving Average Crossover Alert: Akebia (AKBA)
  20. Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.